Lily Li is a Principal at Northpond Ventures on the firm’s life science R&D solutions, molecular diagnostics team. Lily is a Board Director at 1859 and Ansa Bio, and formerly a Board Director at PGDx (acquired). Previously, Lily was at Illumina, where she structured and led strategic partnerships to support company growth across clinical markets. Prior to Illumina, Lily led strategic marketing and business development at NanoString Technologies. Lily was also a management consultant in the life sciences practice at L.E.K. Consulting, where she served as a strategic advisor to a broad range of corporate clients and life science investors. Lily received her Ph.D. in molecular and systems pharmacology from Emory University.
11:00 AM - 12:00 PM (PDT)
Wednesday, June 15